Mon, Apr 21, 2014, 8:42 AM EDT - U.S. Markets open in 48 mins.

Recent

% | $
Quotes you view appear here for quick access.

Alimera Sciences, Inc. (ALIM) Message Board

  • paultradestoday paultradestoday Dec 27, 2010 8:26 AM Flag

    Citi Maintains Buy

    The following is a excerpt from Citi's update:
    Maintain our Buy - We have seen positive Iluvien data out to 30 *
    * months (see Fig. 1) and given that no new clinical trials are *
    * needed and we still believe the product will be approved, so we are *
    * maintaining our Buy. ALIM shares will clearly be under pressure on *
    * Monday (12/27) with shares likely to trade down to the high single *
    * digits. 36 mo. data was set to be presented on 2/12/11 in Miami, *
    * but could now come earlier. *
    * *
    * > Changes to Our Assumptions - We now assume Iluvien is launched in *
    * the US in 1Q12 (from 1Q11) and Europe in 1Q12 (from 3Q11). Our new *
    * US share assumptions are 3% in year 1 (from 5%), 8% in year 2 (from *
    * 9%), and 12% in year 3 (from 13%). *
    * *
    * > Next Steps - ALIM has already put in a request to meet with the *
    * FDA and should hear back from the agency within 30 days. Alimera *
    * expects to file its response (with additional data) to the FDA by *
    * the end of 1Q11 after which point the FDA has 6 months to respond *
    * (end 3Q11). While the FDA could respond sooner than 6 months, we *
    * assume the full period as well as an additional 3 months for label *
    * negotiations, etc. While the FDA decision should not impact EU *
    * approval timing, we now assume a 1Q12 EU launch (from 3Q11) given *
    * that the EU may also want to review the 36 month data. *
    * *
    * > Model changes and Target - Lowering our rev ests. to $0M (from *
    * $164M) in 2011 and to $102M (from $295M) in 2012. Our peak rev est. *
    * for Iluvien is now $800M in 2018 (from $850M in 2017). Target to *
    * $12 based on an unchanged 2.0x EV/Sales multiple on our revised *
    * 2013E revenues of $270M discounted back 2 years at 25%. ALIM has *
    * about $2.80 in cash per share which should last through 2011 *
    * although cash could be tight at the end of 2011 if the company has *
    * any issues accessing its $20M revolver. *
    *

    SortNewest  |  Oldest  |  Most Replied Expand all replies
 
ALIM
6.31+0.01(+0.16%)Apr 17 4:00 PMEDT

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.